Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VBI VACCINES INC.

(VBIV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

VBI Vaccines : Awarded Up to CAD$56 Million Contribution from Canadian Government to Accelerate Coronavirus Vaccine Development

08/05/2020 | 09:07am EDT

- Government of Canada will support advancement of VBI’s coronavirus program through Phase 2 clinical development

- Pre-clinical data are expected to enable selection of clinical candidates in Q3 2020 and the initiation of clinical studies by the end of 2020

Variation Biotechnologies Inc., an Ottawa-based wholly-owned Canadian subsidiary of VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that it has been awarded up to a CAD$56 million contribution from the Strategic Innovation Fund of the Government of Canada to support the development of the company’s coronavirus program, VBI-2900, through Phase 2 clinical studies.

Coronaviruses are enveloped viruses by nature, which make them prime targets for VBI’s flexible enveloped virus-like particle (eVLP) platform technology. A multivalent eVLP vaccine candidate, co-expressing SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins, may enable the immune system’s production of broadly reactive antibodies, potentially offering protection from emerging strains of COVID-19 that evolve over time.

“We are grateful for the support of the Government of Canada and we share their public health commitment to providing an effective response to the ongoing COVID-19 pandemic,” said Jeff Baxter, VBI’s President and CEO. “VBI’s coronavirus program is a differentiated approach, using a proven, scalable, and cost-effective technology to potentially broaden the immune response to SARS-CoV-2 and potentially other coronaviruses. This funding will help accelerate our vaccine candidates into and through clinical development, the first clinical studies for which are expected to initiate by the end of 2020.”

“This investment with VBI is part of Canada’s plan to mobilize science to fight COVID-19,” said Navdeep Bains, Canada’s Minister of Innovation, Science, and Industry. “An effective vaccine will be critical as we work to contain the COVID-19 virus and prevent future infections, and we recognize VBI’s potential to be part of the solution.”

As part of the previously-announced collaboration with the National Research Council of Canada (NRC), a series of three pre-clinical mouse studies initiated in the second quarter of 2020 to evaluate: (1) trivalent vs. monovalent vaccine constructs, (2) multiple different adjuvants, and (3) pre-fusion vs. post-fusion spike proteins. Based on the results of these studies, which are being conducted at both the NRC core facilities and VBI’s research facility in Ottawa, Canada, VBI expects to select the optimal vaccine candidates in the third quarter of 2020 to enable the start of clinical studies by the end of 2020.

In addition to progressing the VBI-2900 program through Phase 2 clinical development, VBI expects to use this funding to finalize all manufacturing process development and to expand the workforce at its research and development facility in Ottawa. Further discussions with the Government of Canada may explore additional federal funding to support late-stage development.

About Coronaviruses

Coronaviruses are a large family of enveloped viruses that usually cause respiratory illness of varying severities, including the common cold and pneumonia. Only seven coronaviruses are known to cause disease in humans, four of which most frequently cause symptoms of the common cold. Three of the seven coronaviruses, however, have more serious outcomes in people: (1) SARS-CoV-2, a novel coronavirus identified as the cause of coronavirus disease 2019 (COVID-19); (2) MERS-CoV, identified in 2012 as the cause of Middle East respiratory syndrome (MERS); and (3) SARS-CoV, identified in 2002 as the cause of an outbreak of severe acute respiratory syndrome (SARS).1,2

About VBI Vaccines Inc.

VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with the only tri-antigenic hepatitis B vaccine, Sci-B-Vac®, which is approved for use and commercially available in Israel, and recently completed its Phase 3 program in the U.S., Europe, and Canada, and with an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI’s enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI’s lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic pan-coronavirus vaccine candidate. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.
Website Home: http://www.vbivaccines.com/
News and Insights: http://www.vbivaccines.com/wire/
Investors: http://www.vbivaccines.com/investors/

Cautionary Statement on Forward-looking Information

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). The Company cautions that such statements involve risks and uncertainties that may materially affect the Company’s results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, the satisfaction of all conditions for the Company’s receipt of the financial contribution from the Canadian Government, including all required governmental approvals and the execution of the definitive contribution agreement, the impact of general economic, industry or political conditions in the United States or internationally; the impact of the recent COVID-19 outbreak on our clinical studies, manufacturing, business plan, and the global economy; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company’s products. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company’s filings with the SEC and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the SEC on March 5, 2020, and filed with the Canadian security authorities at sedar.com on March 5, 2020, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. All such forward-looking statements made herein are based on our current expectations and we undertake no duty or obligation to update or revise any forward-looking statements for any reason, except as required by law.

1 “Coronavirus.” World Health Organization, https://www.who.int/health-topics/coronavirus.
2 “Coronaviruses.” National Institute of Allergy and Infectious Diseases, https://www.niaid.nih.gov/diseases-conditions/coronaviruses


© Business Wire 2020
All news about VBI VACCINES INC.
04/12VBI VACCINES  : Corporate Overview
PU
04/12VBI VACCINES  : Announces Phase 1b/2a Data and Progress of Hepatitis B Immunothe..
BU
04/12VBI VACCINES INC/BC  : Other Events, Financial Statements and Exhibits (form 8-K..
AQ
03/15VBI VACCINES  : to Present at Oppenheimer 31st Annual Healthcare Conference
BU
03/10SECTOR UPDATE : Health Care Stocks Climb Pre-Bell Wednesday
MT
03/10VBI VACCINES  : Coalition to fund VBI to develop vaccines against coronavirus va..
RE
03/10VBI VACCINES  : CEPI to Collaborate to Advance Vaccine Candidates Against COVID-..
MT
03/10VBI VACCINES  : CEPI and VBI Vaccines Collaborate to Advance Vaccine Candidates ..
BU
03/09VBI VACCINES  : Initiates Enrollment in Phase 1/2 Study of COVID-19 Vaccine Cand..
MT
03/09VBI VACCINES  : Announces Initiation of Enrollment in Adaptive Phase 1/2 Study o..
BU
More news
Financials (USD)
Sales 2021 4,95 M - -
Net income 2021 -71,3 M - -
Net Debt 2021 - - -
P/E ratio 2021 -9,77x
Yield 2021 -
Capitalization 688 M 688 M -
Capi. / Sales 2021 139x
Capi. / Sales 2022 11,0x
Nbr of Employees 130
Free-Float 70,3%
Chart VBI VACCINES INC.
Duration : Period :
VBI Vaccines Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VBI VACCINES INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 7,50 $
Last Close Price 2,71 $
Spread / Highest target 232%
Spread / Average Target 177%
Spread / Lowest Target 121%
EPS Revisions
Managers and Directors
NameTitle
Jeffrey R. Baxter President, Chief Executive Officer & Director
Christopher McNulty CFO, Director & Head-Business Development
Steven H. Gillis Chairman
David Evander Anderson Chief Scientific Officer
Francisco Diaz-Mitoma Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
VBI VACCINES INC.5.27%688
MODERNA, INC.53.03%68 414
LONZA GROUP AG-1.83%45 120
IQVIA HOLDINGS INC.20.31%41 337
CELLTRION, INC.-14.21%37 693
SEAGEN INC.-16.92%26 380